Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 3
2016 1
2019 1
2020 2
2023 1
2024 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Emergency changes in international guidelines on treatment for head and neck cancer patients during the COVID-19 pandemic.
Chaves ALF, Castro AF, Marta GN, Junior GC, Ferris RL, Giglio RE, Golusinski W, Gorphe P, Hosal S, Leemans CR, Magné N, Mehanna H, Mesía R, Netto E, Psyrri A, Sacco AG, Shah J, Simon C, Vermorken JB, Kowalski LP. Chaves ALF, et al. Among authors: giglio re. Oral Oncol. 2020 Aug;107:104734. doi: 10.1016/j.oraloncology.2020.104734. Epub 2020 Apr 24. Oral Oncol. 2020. PMID: 32353793 Free PMC article. No abstract available.
Sister partnership to overcome the global burden of cancer.
Magné N, Sotton S, Varges Gomes A, Marta GN, Giglio RE, Mesía R, Psyrri A, Sacco AG, Shah J, Diao P, Malekzadeh Moghani M, Moreno-Acosta P, Bouleftour W, Deutsch E. Magné N, et al. Among authors: giglio re. Br J Radiol. 2024 Dec 1;97(1164):1891-1897. doi: 10.1093/bjr/tqae179. Br J Radiol. 2024. PMID: 39236250 Review.
Predictors of Survival After Head and Neck Squamous Cell Carcinoma in South America: The InterCHANGE Study.
Abrahão R, Perdomo S, Pinto LFR, Nascimento de Carvalho F, Dias FL, de Podestá JRV, Ventorin von Zeidler S, Marinho de Abreu P, Vilensky M, Giglio RE, Oliveira JC, Mineiro MS, Kowalski LP, Ikeda MK, Cuello M, Munyo A, Rodríguez-Urrego PA, Hakim JA, Suarez-Zamora DA, Cayol F, Figari MF, Oliver J, Gaborieau V, Keogh RH, Brennan P, Curado MP; InterCHANGE Group. Abrahão R, et al. Among authors: giglio re. JCO Glob Oncol. 2020 Mar;6:486-499. doi: 10.1200/GO.20.00014. JCO Glob Oncol. 2020. PMID: 32213095 Free PMC article.
Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040).
Pai SI, Faivre S, Licitra L, Machiels JP, Vermorken JB, Bruzzi P, Gruenwald V, Giglio RE, Leemans CR, Seiwert TY, Soulieres D. Pai SI, et al. Among authors: giglio re. J Immunother Cancer. 2019 Apr 3;7(1):96. doi: 10.1186/s40425-019-0578-0. J Immunother Cancer. 2019. PMID: 30944020 Free PMC article. Clinical Trial.
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
Machiels JP, Haddad RI, Fayette J, Licitra LF, Tahara M, Vermorken JB, Clement PM, Gauler T, Cupissol D, Grau JJ, Guigay J, Caponigro F, de Castro G Jr, de Souza Viana L, Keilholz U, Del Campo JM, Cong XJ, Ehrnrooth E, Cohen EE; LUX-H&N 1 investigators. Machiels JP, et al. Lancet Oncol. 2015 May;16(5):583-94. doi: 10.1016/S1470-2045(15)70124-5. Epub 2015 Apr 16. Lancet Oncol. 2015. PMID: 25892145 Clinical Trial.